Progesterone and estrogen receptors: Opposing prognostic indicators in meningiomas

Journal of Neurosurgery

Volumn 105, Issue 2, 2006, Pages 163-173

  Pravdenkova, Svetlana ^a   Al Mefty, Ossama ^a,b   Sawyer, Jeffrey ^a   Husain, Muhammad ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Brain neoplasm; Cytogenetics; Estrogen receptor; Meningioma; Progesterone receptor; Sex steroid; Tumor recurrence

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CHROMOSOME 19; CHROMOSOME ABERRATION; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FISHER EXACT TEST; HISTOLOGY; HISTOPATHOLOGY; HUMAN; KARYOTYPING; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR RECURRENCE;

ADULT; AGED; CELL DIVISION; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 22; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SKULL BASE;

EID: 33747272382     PISSN: 00223085     EISSN: 00223085     Source Type: Journal    
DOI: 10.3171/jns.2006.105.2.163     Document Type: Article

References (87)

1. Al-Mefty O, Kadri PA, Pravdenkova S, Sawyer JR, Stangeby C, Husain M: Malignant progression in meningioma: documentation of a series and analysis of cytogenetic findings. J Neurosurg 101:210-218, 2004
2. KIP1 expression in benign, atypical, and anaplastic meningiomas. Hum Pathol 32:970-975, 2001
3. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, et al: AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277:965-968, 1997
4. Assimakopoulou M: Human meningiomas: immunohistochemical localization of progesterone receptor and heat shock protein 27 and absence of estrogen receptor and PS2. Cancer Detect Prevent 24:163-168, 2000
5. Bello MJ, de Campos JM, Kusak ME, Vaquero J, Sarasa JL, Pestana A, et al: Allelic loss at 1p is associated with tumor progression of meningiomas. Genes Chromosomes Cancer 9:296-298, 1994
6. Bello MJ, de Campos JM, Vaquero J, Kusak ME, Sarasa JL, Rey JA: High-resolution analysis of chromosome arm 1p alterations in meningioma. Cancer Genet Cytogenet 120:30-36, 2000
7. Bickerstaff ER, Small JM, Guest IA: The relapsing course of certain meningiomas in relation to pregnancy and menstruation. J Neurol Neurosurg Psychiatry 21:89-91, 1958
8. Black P, Carroll R, Zhang J: The molecular biology of hormone and growth factor receptors in meningiomas. Acta Neurochir Suppl 65:50-53, 1996
9. Blankenstein MA, Verheijen FM, Jacobs JM, Donker TH, van Duijnhoven MW, Thijssen JH: Occurrence, regulation, and significance of progesterone receptors in human meningioma. Steroids 65:795-800, 2000
10. INK4c) in atypical and anaplastic meningiomas. Am J Pathol 159:661-669, 2001
11. Bouillot P, Pellissier JF, Devictor B, Graziani N, Bianco N, Grisoli F, et al: Quantitative imaging of estrogen and progesterone receptors, estrogen-regulated protein, and growth fraction: immunocytochemical assays in 52 meningiomas. Correlation with clinical and morphological data. J Neurosurg 81:765-773, 1994
12. Bozzetti C, Camisa R, Nizzoli R, Manotti L, Guazzi A, Naldi N, et al: Estrogen and progesterone receptors in human meningiomas: biochemical and immunocytochemical evaluation. Surg Neurol 43:230-234, 1995
13. Brandis A, Mirzai S, Tatagiba M, Walter GF, Samii M, Ostertag H: Immunohistochemical detection of female sex hormone receptors in meningiomas: correlation with clinical and histological features. Neurosurgery 33:212-218, 1993
14. Carroll RS, Brown M, Zhang J, DiRenzo J, Font De Mora J, Black PM: Expression of a subset of steroid receptor cofactors is associated with progesterone receptor expression in meningiomas. Clin Cancer Res 6:3570-3575, 2000
15. Carroll RS, Glowacka D, Dashner K, Black PM: Progesterone receptor expression in meningiomas. Cancer Res 53:1312-1316, 1993
16. Carroll RS, Zhang J, Black PM: Expression of estrogen receptors alpha and beta in human meningiomas. J Neurooncol 42:109-116, 1999
17. Carroll RS, Zhang J, Dashner K, Black PM: Progesterone and glucocorticoid receptor activation in meningiomas. Neurosurgery 37:92-97, 1995
18. Casalone R, Simi P, Granata P, Minelli E, Giudici A, Butti G, et al: Correlation between cytogenetic and histopathological findings in 65 human meningiomas. Cancer Genet Cytogenet 45:237-243, 1990
19. Chu K, Zingg HH: The nuclear orphan receptors COUP-TFII and Ear-2 act as silencers of the human oxytocin gene promoter. J Mol Endocrinol 19:163-172, 1997
20. Cobb MA, Husain M, Andersen BJ, Al-Mefty O: Significance of proliferating cell nuclear antigen in predicting recurrence of intracranial meningioma. J Neurosurg 84:85-90, 1996
21. Ferraraccio F, Accardo M, Giangaspero F, Cuccurullo L: Recurrent and atypical meningiomas - a multiparametric study using Ki67 labeling index, AgNOR and DNA Feulgen staining. Clin Neuropathol 22:187-192, 2003
22. Fewings PE, Battersby RDE, Timperley WR: Long-term follow up of progesterone receptor status in benign meningioma: a prognostic indicator of recurrence? J Neurosurg 92:401-405, 2000
23. Graham JD, Clarke CL: Physiological action of progesterone in target tissues. Endocr Rev 18:502-519, 1997
24. Gursan N, Gundogdu C, Albayrak A, Kabalar ME: Immunohistochemical detection of progesterone receptors and the correlation with Ki-67 labeling indices in paraffin-embedded sections of meningiomas. Int J Neurosci 112:463-470, 2002
25. Hartmann C, Johnk L, Sasaki H, Jenkins RB, Louis DN: Novel PLA2G4C polymorphism as a molecular diagnostic assay for 19q loss in human gliomas. Brain Pathol 12:178-182, 2002
26. Her C, Wood TC, Eichler EE, Mohrenweiser HW, Ramagli LS, Siciliano MJ, Weinshilboum RM: Human hydroxysteroid sulfotransferase SULT2B1: two enzymes encoded by a single chromosome 19 gene. Genomics 53:284-295, 1998
27. Hsu DW, Efird JT, Hedley-Whyte ET: MIB-1(Ki-67) index and transforming growth factor-alpha (TGFα) immunoreactivity are significant prognostic predictors for meningiomas. Neuropathol Appl Neurobiol 24:441-452, 1998
28. Hsu DW, Efird JT, Hedley-Whyte ET: Progesterone and estrogen receptors in meningiomas: prognostic considerations. J Neurosurg 86:113-120, 1997
29. Hsu DW, Pardo FS, Efird JT, Linggood RM, Hedley-Whyte ET: Prognostic significance of proliferative indices in meningiomas. J Neuropathol Exp Neurol 53:247-255, 1994
30. Inoue T, Akahira J, Suzuki T, Darnel AD, Kaneko C, Takahashi K, et al: Progesterone production and actions in the human central nervous system and neurogenic tumors. J Clin Endocrinol Metab 87:5325-5331, 2002
31. Ishino S, Hashimoto N, Fushiki S, Date K, Mori T, Fujimoto M, et al: Loss of material from chromosome arm 1p during malignant progression of meningioma revealed by fluorescent in situ hybridization. Cancer 83:360-366, 1998
32. Jacobsen BM, Richer JK, Sartorius CA, Horwitz KB: Expression profiling of human breast cancers and gene regulation by progesterone receptors. J Mammary Gland Biol Neoplasia 8:257-268, 2003
33. Karamitopoulou E, Perentes E, Tolnay M, Probst A: Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas. Hum Pathol 29:140-145, 1998
34. Koehorst SGA, Jacobs HM, Thijssen JHH, Blankenstein MA: Detection of an oestrogen receptor-like protein in human meningiomas by band shift assay using a synthetic oestrogen responsive element (ERE). Br J Cancer 68:290-294, 1993
35. Koehorst SGA, Jacobs HM, Thijssen JHH, Blankenstein MA: Wild type and alternatively spliced estrogen receptor messenger RNA in human meningioma tissue and MCF7 breast cancer cells. J Steroid Biochem Mol Biol 45:227-233, 1993
36. Kohda T, Asai A, Kuroiwa Y, Kobayashi S, Aisaka K, Nagashima G, et al: Tumour suppressor activity of human imprinted gene PEG3 in a glioma cell line. Genes Cells 6:237-247, 2001
37. Kubo M, Fukutomi T, Akashi-Tanaka S, Hasegawa T: Association of breast cancer with meningioma: report of a case and review of the literature. Jpn J Clin Oncol 31:510-513, 2001
38. Lamszus K, Kluwe L, Matschke J, Meissner H, Laas R, Westphal M: Allelic losses at 1p, 9q, 10q, 14q, and 22q in the progression of aggressive meningiomas and undifferentiated meningeal sarcomas. Cancer Genet Cytogenet 110:103-110, 1999
39. Leone PE, Bello MJ, de Campos JM, Vaquero J, Sarasa JL, Pestaña A, et al: NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas. Oncogene 18:2231-2239, 1999
40. Louis DN, Scheithauer BW, Budka H, von Deimling A, Kepes JJ: Meningiomas, in Kleihues P, Cavenee WK (eds): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Nervous System. Lyon: IARC Press, 2000, pp 176-184
41. Maillo A, Orfao A, Sayagues JM, Diaz P, Gomez-Moreta JA, Caballero M, et al: New classification scheme for the prognostic stratification of meningioma on the basis of chromosome 14 abnormalities, patient age, and tumor histopathology. J Clin Oncol 21:3285-3295, 2003
42. Maiuri F, Montagnani S, Iaconetta G, Gallicchio B, Bernardo A, Signorelli F: Correlation between sex hormone receptors and peritumoral edema in intracranial meningiomas. J Neurosurg Sci 38:29-33, 1994
43. Mandara MT, Ricci G, Rinaldi L, Sarli G, Vitellozzi G: Immunohistochemical identification and image analysis quantification of oestrogen and progesterone receptors in canine and feline meningioma. J Comp Pathol 127:214-218, 2002
44. Maxwell M, Galanopoulos T, Neville-Golden J, Antoniades HN: Expression of androgen and progesterone receptors in primary human meningiomas. J Neurosurg 78:456-462, 1993
45. Mehta D, Khatib R, Patel S: Carcinoma of the breast and meningioma. Association and management. Cancer 51:1937-1940, 1983
46. Menon AG, Rutter JL, von Sattel JP, Synder H, Murdoch C, Blumenfeld A, et al: Frequent loss of chromosome 14 in atypical and malignant meningioma: identification of a putative "tumor progression" locus. Oncogene 14:611-616, 1997
47. Mialhe A, Louis J, Cassanelli S, Seigneurin D: Chromosome 11 aneuploidy detected by fluorescent in situ hybridization (FISH) in breast cancer: relation with progesterone receptor expression. Cytopathology 10:79-86, 1999
48. Miller RE: Breast cancer and meningioma. J Surg Oncol 31:182-183, 1986
49. Mirimanoff RO, Dosoretz DE, Linggood RM, Ojemann RG, Martuza RL: Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg 62:18-24, 1985
50. Nagashima G, Aoyagi M, Wakimoto H, Tamaki M, Ohno K, Hirakawa K: Immunohistochemical detection of progesterone receptors and the correlation with Ki-67 labeling indices in paraffin-embedded sections of meningiomas. Neurosurgery 37:478-483, 1995
51. Nakabayashi H, Shimizu K, Hara M: Prognostic significance of cyclin A expression in meningiomas. Appl Immunohistochem Mol Morphol 11:9-14, 2003
52. Och W, Mariak Z, Kopec J, Smolka M, Koziorowski M: [Correlation of expression of progesterone receptors with histopathological type and grade of malignancy of cerebral neoplasms.] Neurol Neurochir Pol 35 (Suppl 5):110-118, 2001 (Pol)
53. Perry A, Banerjee R, Lohse CM, Kleinschmidt-DeMasters BK, Scheithauer BW: A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas. Brain Pathol 12:183-190, 2002
54. Perry A, Jenkins RB, Dahl RJ, Moertel CA, Scheithauer BW: Cytogenetic analysis of aggressive meningiomas: possible diagnostic and prognostic implications. Cancer 77:2567-2573, 1996
55. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM: Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol 21:1455-1465, 1997
56. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM: The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas. Cancer 82:2262-2269, 1998
57. Pike SE, Yao L, Setsuda J, Jones KD, Cherney B, Appella E, et al: Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth. Blood 94:2461-2468, 1999
58. Piquer J, Cerda M, Lluch A, Barcia Salorio JL, Garcia-Conde J: Correlations of female steroid hormone receptors with histologic features in meningiomas. Acta Neurochir (Wien) 110:38-43, 1991
59. Ritland SR, Ganju V, Jenkins RB: Region-specific loss of heterozygosity on chromosome 19 is related to the morphologic type of human glioma. Genes Chromosomes Cancer 12:277-282, 1995
60. Roser F, Nakamura M, Bellinzona M, Rosahl SK, Ostertag H, Samii M: The prognostic value of progesterone receptor status in meningiomas. J Clin Pathol 57:1033-1037, 2004
61. Rousseau-Merck MF, Bernheim A, Cherif D, Miglierina R, Misrahi M, Loosfelt H, et al: Localization of the human progesterone receptor gene (PGR) to chromosome 11q22-23. Cytogenet Cell Genet 46:685, 1987
62. Rubinstein AB, Loven D, Geier A, Reichenthal E, Gadoth N: Hormone receptors in initially excised versus recurrent intracranial meningiomas. J Neurosurg 81:184-187, 1994
63. Salcman M: Malignant meningiomas, in Al-Mefty O (ed): Meningiomas. New York: Raven Press, 1991, pp 75-85
64. Sandberg DI, Edgar MA, Resch L, Rutka JT, Becker LE, Souweidane MM: MIB-1 staining index of pediatric meningiomas. Neurosurgery 48:590-597, 2001
65. Sawyer JR, Husain M, Pravdenkova S, Krisht A, Al-Mefty O: A role for telomeric and centromeric instability in the progression of chromosome aberrations in meningioma patients. Cancer 88:440-453, 2000
66. Sawyer JR, Swanson CM, Lukacs JL, Nicholas RW, North PE, Thomas JR: Evidence of an association between 6q13-21 chromosome aberrations and locally aggressive behavior in patients with cartilage tumors. Cancer 82:474-483, 1998
67. Scholzen T, Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol 182:311-322, 2000
68. Schrell UM, Adams EF, Fahlbusch R, Greb R, Jirikowski G, Prior R, et al: Hormonal dependency of cerebral meningiomas. Part 1: Female sex steroid receptors and their significance as specific markers for adjuvant medical therapy. J Neurosurg 73:743-749, 1990
69. Seute A, Sinn HP, Schlenk RF, Emig R, Wallwiener D, Grischke EM, et al: Clinical relevance of genomic aberrations in homogeneously treated high-risk stage II/III breast cancer patients. Int J Cancer 93:80-84, 2001
70. Simon M, von Deimling A, Larson JJ, Wellenreuther R, Kaskel P, Waha A, et al: Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: a genetic model of meningioma progression. Cancer Res 55:4696-4701, 1995
71. Smith JS, Tachibana I, Lee HK, Qian J, Pohl U, Mohrenweiser HW, et al: Mapping of the chromosome 19 q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers. Genes Chromosomes Cancer 29:16-25, 2000
72. Speirs V, Boyle-Walsh E, Fraser WD: Constitutive co-expression of estrogen and progesterone receptor mRNA in human meningiomas by RT-PCR and response of in vitro cell cultures to steroid hormones. Int J Cancer 72:714-719, 1997
73. Taddei GL, Caldarella A, Raspollini MR, Taddei A, Buccoliero AM: [Estrogen and progesterone receptors in meningiomas: immunohistochemical (Mib-1, p53) and clinico-morphological correlations.] Pathologica 94:10-15, 2002 (Ita)
74. Teyssier C, Belguise K, Galtier F, Chalbos D: Characterization of the physical interaction between estrogen receptor α and JUN proteins. J Biol Chem 276:36361-36369, 2001
75. Thom M, Martinian L: Progesterone receptors are expressed with higher frequency by optic nerve sheath meningiomas. Clin Neuropathol 21:5-8, 2002
76. Tonn JC, Ott MM, Bouterfa H, Kerkau S, Kapp M, Muller-Hermelink HK, et al: Inverse correlation of cell proliferation and expression of progesterone receptors in tumor spheroids and monolayer cultures of human meningiomas. Neurosurgery 41:1152-1159, 1997
77. Torp SH, Lindboe CF, Granli US, Moen TM, Nordtomme T: Comparative investigation of proliferation markers and their prognostic relevance in human meningiomas. Clin Neuropathol 20:190-195, 2001
78. Tse JY, Ng HK, Lau KM, Lo KW, Poon WS, Huang DP: Loss of heterozygosity of chromosome 14q in low- and high-grade meningiomas. Hum Pathol 28:779-785, 1997
79. Tuccari G, Rizzo A, Muscara M, Giuffre G, Barresi G: PCNA/cyclin expression in breast carcinomas: its relationships with Ki-67, ER, PgR immunostainings and clinico-pathologic aspects. Pathologica 85:47-55, 1993
80. Verhagen A, Go KG, Visser GM, Blankenstein MA, Vaalburg W: The presence of progesterone receptors in arachnoid granulations and in the lining of arachnoid cysts: its relevance to expression of progesterone receptors in meningiomas. Br J Neurosurg 9:47-50, 1995
81. Verheijen FM, Donker GH, Viera CS, Sprong M, Jacobs HM, Blaauw G, et al: Progesterone receptor, bcl-2 and Bax expression in meningiomas. J Neurooncol 56:35-41, 2002
82. von Deimling A, Louis DN, von Ammon K, Petersen I, Wiestler OD, Seizinger BR: Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. Cancer Res 52:4277-4279, 1992
83. Watson MA, Gutmann DH, Peterson K, Chicoine MR, Kleinschmidt-DeMasters BK, Brown HG, et al: Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays. Am J Pathol 161:665-672, 2002
84. Weber RG, Bostrom J, Wolter M, Baudis M, Collins VP, Reifenberger G, et al: Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci U S A 94:14719-14724, 1997
85. Wilson CB: Meningiomas: genetics, malignancy, and the role of radiation in induction and treatment. The Richard C. Schneider Lecture. J Neurosurg 81:666-675, 1994
86. Wolfsberger S, Doostkam S, Boecher-Schwarz HG, Roessler K, van Trotsenburg M, Hainfellner JA, et al: Progesterone-receptor index in meningiomas: correlation with clinico-pathological parameters and review of the literature. Neurosurg Rev 27:238-245, 2004
87. Zattara-Cannoni H, Gambarelli D, Dufour H, Figarella D, Vollot F, Grisoli F, et al: Contribution of cytogenetics and FISH in the diagnosis of meningiomas. A study of 189 tumors. Ann Genet 41:164-175, 1998